Sanofi Pasteur, a Sanofi Company: clinical-trial pipeline
Sanofi Pasteur, a Sanofi Company is the sponsor of 2,215 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 169 are not yet finished and 7 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials169
Phase 2/3 and 3773
Countries105
New in 90 days7
Trials by phase
| Phase | Trials |
|---|---|
| Phase 3 | 752 |
| Phase 2 | 479 |
| Phase 4 | 382 |
| Phase 1 | 304 |
| Not applicable | 185 |
| Phase 1/2 | 92 |
| Phase 2/3 | 21 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 1,794 |
| Terminated | 229 |
| Recruiting | 83 |
| Active, not recruiting | 72 |
| Withdrawn or not authorised | 19 |
| Not yet recruiting | 14 |
| Unknown | 3 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 430 |
| Infectious disease and vaccines | 364 |
| Metabolic and endocrine (diabetes, obesity) | 316 |
| Immunology and rheumatology | 182 |
| Cardiovascular | 176 |
| Rare and genetic diseases | 141 |
| Respiratory | 140 |
| Gastroenterology and liver | 108 |
| Nephrology and urology | 96 |
| Neurology | 93 |
| Dermatology | 75 |
| Haematology | 75 |
Countries
| Country | Trials |
|---|---|
| United States | 1,082 |
| France | 528 |
| Germany | 457 |
| Canada | 426 |
| Spain | 421 |
| Italy | 378 |
| United Kingdom | 347 |
| Brazil | 288 |
| Poland | 278 |
| Netherlands | 271 |
| Australia | 268 |
| Belgium | 266 |
| Czechia | 256 |
| Argentina | 242 |
| Japan | 240 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza V… |
| 2026-10-06 | New trial posted | Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at… |
| 2026-10-02 | New trial posted | An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1… |
| 2026-10-01 | New trial posted | Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Part… |
| 2026-09-10 | New trial posted | A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Modera… |
| 2026-09-09 | New trial posted | Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Prot… |
| 2026-08-28 | New trial posted | A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clin… | Phase 2 | Recruiting | Australia, Brazil, Chile, China +13 |
| NCT06141473 | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | United Arab Emirates, Argentina, Austria, Belgium +37 |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Par… | Phase 2 | Active, not recruiting | Australia, Brazil, China, Czechia +3 |
| NCT04936685 | Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administ… | Phase 3 | Active, not recruiting | Germany, Spain, Finland, Hungary |
| NCT05405166 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | Phase 3 | Active, not recruiting | Argentina, Australia, Brazil, Canada +16 |
| NCT06241118 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids… | Phase 3 | Active, not recruiting | United Arab Emirates, Argentina, Australia, Brazil +18 |
| NCT06290128 | A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyn… | Phase 3 | Active, not recruiting | Argentina, Belgium, Bulgaria, Brazil +19 |
| NCT05280548 | A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult… | Phase 3 | Active, not recruiting | Austria, Canada, China, Czechia +14 |
| NCT05206773 | A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Par… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Brazil +16 |
| NCT06407934 | A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compar… | Phase 3 | Active, not recruiting | Argentina, Australia, Bulgaria, Brazil +22 |
| NCT05097287 | Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients Wi… | Phase 4 | Active, not recruiting | United Arab Emirates, Belgium, Bulgaria, Brazil +18 |
| NCT06290141 | A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobu… | Phase 3 | Recruiting | Argentina, Belgium, Brazil, Canada +20 |
| NCT02991469 | A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arth… | Phase 2 | Not yet recruiting | Argentina, Bulgaria, Canada, Germany +12 |
| NCT05222906 | Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease… | Phase 3 | Active, not recruiting | Argentina, Canada, China, Germany +6 |
| NCT05164055 | Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) | Phase 4 | Active, not recruiting | France |
| NCT04879628 | Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis | Phase 2 | Active, not recruiting | Bulgaria, Canada, Czechia, Germany +5 |
| NCT01736592 | Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration | Phase 2 | Active, not recruiting | France, United States |
| NCT06557772 | A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac… | Phase 2 | Active, not recruiting | Argentina, Australia, Belgium, Brazil +16 |
| NCT02065011 | A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With… | Phase 2 | Active, not recruiting | France, United States |
| NCT05897424 | Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Active, not recruiting | Australia, Denmark, Spain, United Kingdom +5 |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and De… | Phase 3 | Active, not recruiting | Australia, Belgium, China, Czechia +16 |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | Phase 1/2 | Recruiting | Australia, Germany, France, Greece +6 |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced S… | Phase 1/2 | Recruiting | Chile, Spain, Israel, Japan +2 |
| NCT06141486 | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multipl… | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Bulgaria +22 |
| NCT06630806 | A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants Wit… | Phase 1 | Recruiting | Australia, Canada, Spain, France +3 |
Hiring for clinical development
Sanofi Pasteur, a Sanofi Company has 39 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites: hiring profile of sanofi.com.
Website: sanofi.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Sanofi Pasteur, a Sanofi Company clinical trials: 169 open, 773 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/sanofi-com/, data as of 2026-10-25.